Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PGV002 in Advanced Solid Tumors
NCT05359354Phase 1Recruiting
- Start
- Sep 2022
- Primary completion
- Sep 2025
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of PGV002 in solid tumor (2 arms). Primary endpoints: Maximum Tolerated Dose at 16 weeks, Dose-Limiting Toxicity at 16 weeks and 1 more. Started Sep 2022; status: recruiting.
02
Drugs
PGV002
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05359354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05359354.